In this regard, single domain antibodies have been rationally designed to specifically inhibit the aggregation of α-syn, amylin (the causative agent of islet amyloid in type-2 diabetes, IAPP) and Aβ [68,69]. The gene discussed is IAPP; the disease is type 2 diabetes mellitus.